AOD-9604 research guide for 00. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
The research peptide community in 00 connects to global networks focused on compounds like AOD-9604 — researchers in 00 access shared experience about vendor quality that crosses geographic boundaries. The fundamental verification approach for AOD-9604 — reading COAs, understanding HPLC data, evaluating endotoxin results — is identical for all researchers across 00. 00's position in the research peptide supply chain is primarily as a destination market served by international vendors — the COA and storage requirements are no different from global research community norms. What follows addresses the core quality standards for AOD-9604 with 00-specific sourcing and shipping context added for researchers in 00.
How AOD-9604 Works
The oral bioavailability of MK-677 (Ibutamoren) distinguishes it from other compounds in the GHS class and has research design implications for 00 researchers. As an oral GHS, MK-677 avoids the technical requirements of injectable administration, making it more accessible for longer-term studies in non-specialized settings. Its half-life of approximately 24 hours produces a sustained GH elevation pattern, different from the acute pulsatile stimulation of injectable GHRPs. 00 researchers selecting between AOD-9604 options should consider whether acute pulsatile GH stimulation or sustained GH elevation is more relevant to their specific research question.
00 researchers sourcing AOD-9604 should plan around typical shipping timelines: international peptide shipments to 00 typically take between 5 and 15 business days depending on vendor location and shipping method. Payment and currency options may also differ for 00 researchers — vendors that accept multiple payment methods including payment channels that work in 00 reduce barriers to completing a purchase. Storage infrastructure is a practical consideration 00 researchers should prepare before sourcing AOD-9604 — lyophilised peptides require −20°C storage, and ordering large quantities without proper storage in place is wasteful. The three steps that cover the majority of sourcing risks for 00 researchers: community reputation check, COA verification, and 00 shipping confirmation — these take less than an hour and substantially reduce quality and import risks.
AOD-9604: Storage, Reconstitution & Protocols
AOD-9604 is a research compound unapproved for therapeutic human use — storage: lyophilised at minus 20°C, reconstituted solution refrigerated at 2-8°C and used within 30 days with bacteriostatic water. Sterile reconstitution means: alcohol swab on vial septum, fresh needle, clean preparation surface — do not use reconstituted AOD-9604 that appears turbid or shows particulate. These three steps define responsible AOD-9604 research in 00 and across all markets: quality sourcing from a vendor with complete COA data, proper handling with appropriate temperature control, and clear protocol records for contextualising any unusual findings.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
